No Data
No Data
Glad Cube, C&S, and others.
<3479> Revision above, expected operating profit for this term is 8.2 billion yen ← 7.35 billion yen. <4076> Established medium-term management plan for the term from May 25, 2027 to May 25, 2027, with a sales target of 10 billion yen for the term ending May 25, 2027. <4883> Mass exercise of 12th new share subscription rights (with exercise price adjustment clause) from Modalis, the number of shares to be awarded from the 11th, 0.85 million shares. Large-scale exercise of the first unsecured convertible bond type new share subscription rights with conversion price adjustment clause, with the number of shares to be awarded from the 3rd, 1.42 million 8568 shares.
Modalis Therapeutics Teams Up With GENIXCURE
Modalis Therapeutics Sets Exercise Price for New Stock Option Program
Modalis Therapeutics (TYO:4883) finalized the terms of its 13th stock option program, setting the exercise price for share acquisition rights at 7,400 yen per unit, according to a Monday filing with t
Modalis Therapeutics Sets Terms for New Stock Options
GreenEnergy & Company, PRISM BioLab, etc.
<1436> GreenEnergy & Company Co., Ltd. Shareholding ratio of SBI Securities Co., Ltd.: 5.29% → 1.31% Reporting obligation date: June 28, 2024 <202A> K2 Top Holdings Co., Ltd. Shareholding ratio of Mamezou Digital Holdings Co., Ltd. and Mamezou K2 Top Holdings Co., Ltd.: -% → 71.78% Reporting obligation date: June 27, 2024 <206A> PRISM BioLab Co., Ltd., Eli Lilly.
Modalis Therapeutics to Reduce Headcounts at US Subsidiary to Lower Expenses by 35 to 40 Million Yen in Fiscal 2024
Modalis Therapeutics' (TYO:4883) corporate restructuring to reduce the headcount at its US subsidiary, by five positions by the end of July, is expected to lower expenses by 35 to 40 million yen for t
No Data